Unmasking Type – 1 Diabetes Mellitus Following an Episode of Euglycemic Diabetic Ketoacidosis with SGLT-2 Inhibitor Use: A Case Report
Abstract
We describe here the case of a patient with Euglycemic DKA in the setting of SGLT-2 inhibitor use, further evaluation of which led to unmasking of Type-1 Diabetes Mellitus. There have been previous case reports where SGLT-2 inhibitor use has led to unmasking of diabetes mellitus type-1 in patients previously diagnosed with diabetes mellitus type-2. We had a 57-year-old female with history of type 2 DM since last 10-12 years on Empagliflozin, Liraglutide, Metformin, Glimepiride and Pioglitazone presented with 5-hour history of shortness of breath which was acute in onset and was not associated with any other complaints. On initial evaluation, random blood sugar was 182 mg/dl. ABG showed high anion gap severe metabolic acidosis and Serum ketones levels were high. She was treated with IV fluids in the form of normal saline and was later switched to dextroseinfusion when her random blood sugar levels fell below 250 mg/dl, Insulin infusion and Potassium correction along with other supportive measures. her symptoms resolved with treatment over 3-4 days. We did a literature review on the topic and present here the pathophysiology, Diagnosis, Management and Prevention of SGLT-2 inhibitor induced Euglycemic DKA. Case Study Jha et al.; AJRRE, 3(1): 1-5, 2020; Article no.AJRRE.57311 2
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.